Key facts
- It has raised $3.1M.
- Notable investors include Tech Incubator Program for Startup, IBK Changgong, Korea Credit Guarantee Fund, Matter (Consulting Services (B2B)), Center for Creative Economy and Innovation — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for THYROSCOPE
- ·The full record, as it builds
Funding rounds
No funding rounds for THYROSCOPE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About THYROSCOPE
Developer of a wearable-based digital monitoring solution designed for patients with thyroid dysfunction (TDF) and thyroid eye disease (TED) empowering them to monitor disease progression and risks in daily life. The company's therapeutics detect thyroid dysfunction and the user's thyroid hormone level using biometric information and heart rate, their goal is to deliver innovative, data-driven solutions for patients, healthcare providers, and other stakeholders in thyroid care, enabling customers to receive a real-time diagnosis without blood tests at the hospital.
- Sector
- Healthcare
- HQ
- Ulsan, South Korea
- Founded
- 2020
- Employees
- 31
- Website
- thyroscope.com/
- Ownership
- Privately Held (backing)
THYROSCOPE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in THYROSCOPE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on THYROSCOPE in its N-PORT filings yet. We sweep new filings monthly.